Systemic treatment in intermediate stage (Barcelona Clinic Liver Cancer-B) hepatocellular carcinoma
DS Karagiannakis - Cancers, 2023 - mdpi.com
Simple Summary According to the latest BCLC algorithm, the reference treatment of BCLC-B
HCCs that are non-eligible for surgery or liver transplantation is trans-arterial …
HCCs that are non-eligible for surgery or liver transplantation is trans-arterial …
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
J Liu, S Xia, B Zhang, DM Mohammed, X Yang, Y Zhu… - Discover Oncology, 2024 - Springer
Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of
cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of …
cancer death in the world, and hepatocellular carcinoma (HCC) is the most common form of …
Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial‐level analysis
GA Colloca, A Venturino - Cancer, 2024 - Wiley Online Library
Background In a disease like unresectable hepatocellular carcinoma, overall survival is an
inadequate outcome measure for evaluating the effectiveness of treatments given the high …
inadequate outcome measure for evaluating the effectiveness of treatments given the high …
Application and impact of antiviral therapy for patients with HBV-related hepatocellular carcinoma receiving sorafenib and lenvatinib treatment
Overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) has
improved in the era of multi-line sequential therapy. The application of antiviral therapy and …
improved in the era of multi-line sequential therapy. The application of antiviral therapy and …
[PDF][PDF] The prognostic role of albumin-bilirubin grade in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
XR Shi, XY Xu, GL Zhang, JY Jiang… - European Review for …, 2022 - europeanreview.org
OBJECTIVE: Our aim was to explore the prognostic role of baseline albumin-bilirubin levels
(ALBI) on the efficacy of immunotherapy in patients with advanced non-small cell lung …
(ALBI) on the efficacy of immunotherapy in patients with advanced non-small cell lung …
Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
SF Huang, SW Chong, CW Huang, HY Hsu, KT Pan… - Biomedicines, 2022 - mdpi.com
Sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). However,
there is no evidence for a response of different target lesions to sorafenib administration …
there is no evidence for a response of different target lesions to sorafenib administration …
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma
K Tajiri, N Muraishi, A Murayama… - Hepatology …, 2024 - Wiley Online Library
Aim Sequential therapies are essential to extend overall survival (OS) in patients with
unresectable hepatocellular carcinoma (HCC). Several second‐line treatments with …
unresectable hepatocellular carcinoma (HCC). Several second‐line treatments with …
Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and …
Background The use of regorafenib in the treatment of hepatocellular carcinoma (HCC) is
widespread. Albumin-Bilirubin (ALBI) has been shown to be a potential prognostic marker …
widespread. Albumin-Bilirubin (ALBI) has been shown to be a potential prognostic marker …